GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MIL:1INCY) » Definitions » Valuation Rank

Incyte (MIL:1INCY) Valuation Rank


View and export this data going back to 2023. Start your Free Trial

What is Incyte Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Incyte Valuation Rank Related Terms

Thank you for viewing the detailed overview of Incyte's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MIL:1INCY) » Definitions » Valuation Rank
Comparable Companies
SMMT INSM BMRN MRNA RPRX TECH PCVX UTHR SRPT EXEL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
INCY:USA INCY:Mexico 0J9P:UK ICY:Germany ICY:Germany I1NC34:Brazil
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Website
https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.